Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 2/20 | 0.57 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | TTK | P33981 | 7/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279212 | 0.87 | BRD4 (0.53) | PTK2BRD4JAK2EGFRTTK | |
| SCHEMBL3283903 | 0.81 | PDGFRA (0.68) | PTK2BRD4JAK2EGFRPDGFRB | |
| SCHEMBL3283548 | 0.80 | LRRK2 (0.57) | PTK2BRD4JAK2TTKPDGFRB | |
| SCHEMBL3280654 | 0.80 | EGFR (0.62) | PTK2BRD4JAK2EGFRPDGFRB | |
| SCHEMBL14547762 | 0.79 | CYP1A2 (0.42) | PTK2BRD4JAK2TTKPDGFRB | |
| SCHEMBL3283669 | 0.78 | JAK2 (0.55) | PTK2BRD4JAK2EGFRTTK | |
| SCHEMBL3283451 | 0.78 | PTK2 (0.57) | PTK2BRD4JAK2EGFRTTK | |
| SCHEMBL14547697 | 0.77 | PAK4 (0.51) | PTK2TTKJAK3BTK | |
| SCHEMBL13951275 | 0.77 | PTK2 (0.58) | PTK2BRD4JAK2EGFRTTK | |
| SCHEMBL1018484 | 0.76 | PTK2 (0.59) | PTK2BRD4JAK2EGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | PTK2 196/4885BRD4 716/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.